FINWIRES · TerminalLIVE
FINWIRES

$LGND

8 stories mentioning LGNDUpdated 16d ago

Every FINWIRES story that references LGND, newest first.

Wire

Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase

Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday.XOMA Royalty shareholders received $39 in cash per share and one non-transferable contingent value right tied to a portion of proceeds from certain pending litigation, the company said.Ligand said the acquisition adds seven commercial products, 14 late-stage development programs and more than 100 development and commercial-stage assets.The company said the transaction is expected to add about $0.50 per share and $1.50 per share to its projected adjusted earnings per share in 2026 and 2027, respectively.Ligand said it expects to provide an updated five-year outlook at its Investor Day on Dec. 8.Following the closing, XOMA Royalty's common stock stopped trading on the Nasdaq Global Market, the company said.Price: $307.59, Change: $-1.66, Percent Change: -0.54%

$LGND$XOMA
Wire

Ligand Pharmaceuticals Plans $550 Million Convertible Notes Offering Due 2031

Ligand Pharmaceuticals (LGND) intends to raise $550 million through a private placement of convertible senior notes due 2031, the company said Monday.The company said it expects to grant initial purchasers a 13-day option to purchase up to an additional $82.5 million of notes.Ligand said it will use part of the proceeds for hedging transactions and up to $75 million for share buybacks to offset dilution, with the remainder for general corporate purposes, including investing in complementary businesses, companies, products and technologies.Shares of the company were down 3% in premarket trading.

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $544,830, According to a Recent SEC Filing

Stephen L Sabba, Director, on June 16, 2026, sold 2,145 shares in Ligand Pharmaceuticals (LGND) for $544,830. Following the Form 4 filing with the SEC, Sabba has control over a total of 33,629 common shares of the company, with 33,629 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/xslF345X05/tm2618247-1_4seq1.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,651,320, According to a Recent SEC Filing

Jason Haas, Director, on June 12, 2026, sold 6,461 shares in Ligand Pharmaceuticals (LGND) for $1,651,320. Following the Form 4 filing with the SEC, Haas has control over a total of 4,981 common shares of the company, with 4,981 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/xslF345X05/edgardoc.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing

Andrew Reardon, Chief Legal Officer & Secretary, on June 01, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,135,316. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,382 common shares of the company, with 41,382 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/xslF345X05/edgardoc.xml

$LGND
Insider Trading

Ligand Pharmaceuticals Insider Sold Shares Worth $563,080, According to a Recent SEC Filing

John W Kozarich, Director, on May 01, 2026, sold 2,501 shares in Ligand Pharmaceuticals (LGND) for $563,080. Following the Form 4 filing with the SEC, Kozarich has control over a total of 41,786 common shares of the company, with 41,786 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/xslF345X05/edgardoc.xml

$LGND
Wire

RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating

Ligand Pharmaceuticals (LGND) has an average rating of buy and mean price target of $257.44 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $218.14, Change: $+7.81, Percent Change: +3.71%

$LGND
Sectors

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.

$IBB$LGND$OGN$ORKA$XLV$XOMA

Track with the FINWIRES app suite

FolioX
FolioX
Track LGND in your portfolio
WheelAI
WheelAI
Analyze LGND options with the wheel strategy
StockInsider
StockInsider
See market sentiment on LGND